2 active not recruiting, 1 completed, 1 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Withdrawn 1 |
Follow FMT Capsule DE: new trials by email Literature Review of FMT Capsule DE trials Research Report on FMT Capsule DE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation Fecal Microbiota Transplantation Capsule, Placebo - Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 157 | 2023-12-12 | 2026-10-20 |
| Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients FMT Capsule DE, Placebo oral capsule - Clostridium Difficile Infection | Phase 2 | Withdrawn | University of Wisconsin, Madison | 2022-09-01 | 2021-02-23 | |
| Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule - Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2021-02-22 | 2026-06-12 |
| The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule - Clostridium Difficile Infection, C.Difficile Diarrhea | Phase 2 | Completed | University of Wisconsin, Madison | 1 | 2019-03-21 | 2021-03-15 |
Clostridium Infections (2) · Colorectal Neoplasms (1)
University of Wisconsin, Madison (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (3)
Armin Rashidi (1) · Michael J Overman (1) · Nasia Safdar, MD PhD (1) · Nasia Safdar, MD, PhD (1)
P50CA221707 (1)